Peptide Research Guides

Synthetic pentadecapeptide (15 AA) derived from gastric juice protective protein. Studied for angiogenesis via VEGFR2 upregulation, NO pathway modulation, and multi-tissue repair in musculoskeletal, GI, and neural research models.

Long-acting triple incretin receptor agonist with C20 fatty diacid modification for albumin binding. Phase 2 clinical candidate (Eli Lilly). Research focus: energy metabolism, body composition, appetite regulation via tripartite receptor activation.

Synthetic heptapeptide analogue of ACTH(4-7) with Pro-Gly-Pro C-terminal stabilisation. Studied for BDNF/NGF/NT-3 upregulation, monoamine modulation (DA, 5-HT, NA), and neuroprotection in ischaemia models. Approved pharmaceutical in Russia/Ukraine.

Synthetic Thymosin β4 fragment studied for actin sequestration, cellular motility enhancement, angiogenesis, and stem-cell mobilization to sites of tissue injury in musculoskeletal and dermal repair models.

Naturally occurring copper tripeptide found in human plasma. Studied for collagen synthesis signaling, wound healing modulation, antioxidant activity, and DNA repair gene expression in dermal research models.

Selective pentapeptide GH secretagogue. Studied for clean pulsatile GH release without significant cortisol or prolactin co-elevation. GH axis, IGF-1, and body composition research applications.

16-amino-acid mitochondria-encoded peptide. Studied for folate cycle inhibition, AICAR accumulation, AMPK activation, and exercise-induced nuclear retrograde signaling in metabolic homeostasis research.

Synthetic heptapeptide tuftsin analogue with Pro-Gly-Pro stabilisation. Studied for anxiolytic activity via IL-6 modulation and BDNF elevation without benzodiazepine-class receptor binding in CNS research.

Small-molecule selective NNMT inhibitor. Studied for intracellular NAD⁺ elevation, SIRT1 activation, and thermogenic effects in white adipose tissue research models. Orally bioavailable, room-temperature stable.

44-amino-acid synthetic GHRH analogue with trans-3-hexenoic acid modification for enzymatic resistance. Studied for selective visceral adipose tissue (VAT) reduction and pulsatile endogenous GH release patterns.

Dual GIP and GLP-1 receptor agonist with exceptional binding affinity. Studied for beta-cell function improvement, insulin sensitivity modulation, delayed gastric emptying, and satiety signaling in metabolic disorder research.

Synthetic tetrapeptide derived from natural pineal-gland extracts. Studied for telomerase activation, telomere maintenance, and regulation of melatonin-associated circadian pathways in longevity research models.

Tetrasubstituted GHRH(1-29) analogue with enhanced enzymatic stability. Studied for pulsatile GH release via somatotroph GHRH receptor binding. Frequently paired with GHSR agonists for synergistic research protocols.